Background: Quality of life (QOL) assessment has emerged to measure and quantify the balance between treatment benefit and toxicity, and has a value in predicting response and overall survival in cancer patients.
INTRODUCTION
The role of chemotherapy is still controversial in advanced non-small cell lung cancers (NSCLCs) due to the fact that prolonged survival is dismal in these groups. Given this fact, palliation of symptoms is a major goal of management and radiation therapy plays an important role in this regard. Over the past decade, combination chemotherapies, most containing cisplatin, have produced higher response rates and improved survival (1-4). However, the survival benefit is clearly modest and complete responses are rare; there is a need to balance the benefit gained in terms of symptomatic improvement against toxicity of chemotherapy and the purpose of quality oflife (QOL) assessment is to measure and quantify this balance (5) (6) (7) . In response to this awareness, a number of disease-specific QOL instruments have been developed in recent years (9) (10) (11) (12) . Assessment of QOL of cancer patients in clinical trials is generally composed of two basic elements: a core QOL questionnaire covering general aspects of health-related QOL, and additional disease-or treatment-specific questionnaires.
MIP (mitomycin, ifosfamide and cisplatin) is composed of three active agents for NSCLC. With moderate-dose cisplatin (50 mg/m-), it is tolerable without serious toxicity (13) . In this paper, we report the QOL assessment, including health-related QOL and disease-specific symptoms, in advanced NSCLC to address the importance of QOL in the prediction of response to and survival with MIP chemotherapy in advanced lung cancer patients.
MATERIALS AND METHODS
Patients with histologically or cytologically documented inoperable NSCLC were eligible for entry to this trial. Additional eligibility criteria included the following: measurable and/or assessable lesions, age less than 75 years, Eastern Cooperative Oncology Group (ECOG) performance status less than three, and adequate bone marrow reserve, liver and renal functions, and a life expectancy of more than three months. No prior chemotherapy and/or radiotherapy were allowed. Furthermore, suitability for follow-up evaluation and informed consent were required. Patients with symptoms or signs considering palliative radiation therapy, such as brain metastasis, painful bone metastasis, bronchial obstruction or massive hemoptysis, were excluded.
Before study entry, patients were evaluated by physical examination, laboratory tests including blood counts, blood chemistries, urinalysis, chest X-ray, ECG, bone scan, and computed tomography (CT) scan of the chest. Before every cycle of chemotherapy, chest X-ray, blood counts and blood chemistries were performed. CT scan of the brain was not routinely required, but was performed in the presence of neurological symptoms.
All patients received the following combination chemotherapy: mitomycin (6 mg/m-), ifosfamide (3000 mg/m-) and cisplatin (50 mg/m-') intravenously on day 1. The regimen was repeated every three weeks and continued until progression of disease, fall in performance status, or to a maximum of six cycles. On progression, no restrictions were posed on secondary treatments.
Standard World Health Organization (WHO) criteria for response and toxicity assessment were used. The response to chemotherapy was evaluated after every second cycle of chemotherapy. Patients were assessable for toxicity after at least one course of chemotherapy and for response after at least two courses, unless rapid progression of the disease was evident earlier. Patients were monitored until death or until the time analysis. The duration of response and survival were calculated from the date of entry onto this trial. 
RESULTS

PATIENT CHARACTERISTICS
Between July 1995 and February 1997,38 patients were entered into the study and 36 were evaluable for response and toxicity. Two patients were excluded from the analysis because they refused further treatment after the first cycle of chemotherapy. The characteristics of all patients are summarized in Table 1 . The majority of patients were male (78.9%) and had good performance status (PS) equal to or less than one (by ECOG) (73.7%). A total of 116 cycles were delivered with a median of three (range 1-7 cycles) per patient. The median duration of follow-up was seven months (range 2-23 months).
RESPONSE
No patients obtained a complete response (CR) and 14 patients obtained a partial response (PR) for an overall response rate of 38.9%. The median duration of response was 3.5 months (range: 2.0-4.0 months, 95% CI). No significant difference in terms of response was noted between differing age, histology, clinical stage or baseline QOL ( Table 2 ). experienced greater than grade two myelosuppression. There was no dose reduction or delay due to toxicity (Table 4) . (Fig. 1) . Among L.A.S .A. scales, feeling of well-being and lung cancer-specific symptoms were mostly improved. Compliance with the protocol diminished with the course of chemotherapy. Although the assessment of QOL was available in all patients at baseline and six weeks, it was only available in 10 and five patients at 12 and 18 weeks, respectively.
OVERALL SURVIVAL
The median survival was seven months (range: 5.9-8.5 months, 95% CI) and survival at one year was 37.9% [standard error (SE), 12.7%]. During follow-up, 17 patients died due to the progression of disease (16 patients) and sepsis not related to treatment (one patient). Change of QOL from baseline to the subsequent six week assessment correlated highly with survival (correlation coefficient 0.61); we therefore placed patients into two groups, those with QOL improvement (n =21) and those without QOL improvement (n = 15), and evaluated the prognostic value for survival with other multiple clinical factors (age, histology, clinical stage, PS). Univariate analysis of prognostic variables for overall survival showed that change of QOL and age were statistically significant (P = 0.003 and 0.005, respectively). In multivariate analysis, only change of QOL was significant (P = 0.0007) with an estimated relative risk of 2.7 for patients without QOL improvement (Table 5 ). 
DISCUSSION
Because of the complex relationship between treatment benefit and toxicity, careful measurement and documentation of patients' functional status has become a necessary component of outcome evaluation in many clinical trials (5-7). QOL assessment has emerged to measure and quantify the balance between treatment benefit and toxicity, and has a value in predicting response and overall survival (7, 8) .
Advanced lung cancer patients reported the poorest QOL and were frequently selected as the initial target population for QOL study in clinical trials due to the high incidence and the relatively rapid progression of the disease, facilitating both patient accrual and evaluation of responsiveness of the questionnaire to change in health status over time (9) (10) (11) (12) . Theoretically, the relative benefit and impact of treatment for NSCLC should be central in the evaluation of the treatment, and overall survival and response were traditionally used as the end points of the clinical trials. However, these factors are inadequate in the evaluation of treatment policy of advanced NSCLC with only modest survival benefit, even, which may be substantially improved with new agents. There is a strong need for QOL as an end point of treatment in advanced NSCLC in order that doctors and their patients can effectively discuss the trade-off of treatment (5-7), yet many clinicians seem reluctant to turn the emphasis away from the traditional end points of response and survival to QOL. We believe that in cancer therapy, equal emphasis should be given to the patient's QOL as well as to objective measurement of response.
A meta-analysis of all randomized trials comparing chemotherapy to supportive care (including palliative radiation therapy) alone in patients with advanced NSCLC was completed in 1994. This translated into an absolute improvement of median survival of two months and a 10% increase in one-year survival (14). Given these modest therapeutic benefits, no chemotherapy program can be recommended as the standard treatment for NSCLC. MIP combination is one of the most frequently used in the palliative setting of NSCLC with a response rate between 30 and 40% (13, 15) . There have been reports of chemotherapy leading to significant palliation and improvement of overall QOL including patients failing to achieve an objective response. The relatively high incidence of symptomatic relief (75%) was seen in MVP (mitomycin, vinblastine and moderate-dose cisplatin) chemotherapy compared to the modest objective response rate of 21% (13, 16) . A recent ECOG trial suggested that QOL change data were the most significant prognostic factor of survival in patients with NSCLC (8) .
Well-defined and constructed QOL instruments are available to measure QOL, and these are proved to have practicality, validity and reliability in clinical trials (5-7). However, there are a few discrepancies and difficult problems between theory and practice. When assessing palliation, symptoms can be quantified by QOL measures and analyzed statistically, but there is no agreement regarding the definition of palliation and the clinical correlating factors for changes in QOL scores are unknown. Interpretation of data by statistical analysis is proving difficult and complex in practice. Often, patients and/or protocol compliance and missing data can affect the quality of QOL. Usually, compliance diminishes with the successive courses of therapy due to worsening of PS, progressive disease or death (17) . We used the baseline and six-week QOL data because patients and/or protocol compliance diminished after two cycles of chemotherapy due to patient death or worsening of PS, failure to attend clinic, or administrative failure.
In this study, our central concern of QOL was symptomatic palliation including lung cancer-specific and general symptoms. In a small clinical trial, like ours, disease-specific or general symptoms have been used as QOL assessment (17) . The attending physician completed the QOL-questionnaire in this study. What we needed was a readily comprehensive, convenient and reliable way for patients to make their own assessment as to their QOL before and after treatment. Priestman and Baum (19) used L.A.S.A. scales to measure 10 arbitrarily chosen aspects of the QOL of patients with cancer. They found that the change in -!:-.A.S.A. scales correlated well with the objective response to treatment. The reliability of the assessment technique proved the high correlation between the scores for patients alone and with a doctor present (18, 19) .
The feature of this study was a high incidence of improved QOL (58.3%) despite a modest and short-lived response (38.9%, median 3.5 months). QOL improvement was possible without serious morbidity. Finally, a change of QOL was significant in predicting survival and integral QOL studies in a clinical trial would be expected to provide the enhanced clinical outcome.
The incidence of lung cancer is increasing and the arrival of new drugs will bring a potential for improvement in treatment. However, most patients are diagnosed at an advanced stage, and it is essential to integrate the logically implement QOL research and data recording in treatment policy for improving patient care.
